Tuesday, 28 January 2014

Pfizer beats profit estimates, investors eye experimental drugs


The Pfizer logo is seen next to a U.S. flag in a conference room at their world headquarters in New York Pfizer Inc reported better-than-expected fourth-quarter results, helped by higher sales of drugs for cancer, nerve pain and arthritis, and forecast 2014 earnings in line with Wall Street estimates. The biggest U.S. drugmaker said on Tuesday it earned $2.57 billion, or 40 cents per share, in the fourth quarter. Excluding special items, Pfizer earned 56 cents per share. Schott said investors remain focused mainly on the company's pipeline of experimental drugs, including a breast cancer treatment called palbociclib and studies to determine whether Pfizer's blockbuster Prevnar vaccine against pneumococcal bacteria can prevent pneumonia in adults age 65 and older.








via Health News Headlines - Yahoo News Read More Here..


Lake forest health and fitness http://ift.tt/1f8k1vz

No comments:

Post a Comment